Literature DB >> 10623814

uPA/uPAR system is active in immature dendritic cells derived from CD14+CD34+ precursors and is down-regulated upon maturation.

E Ferrero1, K Vettoretto, A Bondanza, A Villa, M Resnati, A Poggi, M R Zocchi.   

Abstract

We recently described a subset of peripheral CD14+CD34+ cells able to migrate across endothelial cell monolayers and differentiate into immunostimulatory dendritic cells (DC). In this paper we show that immature DC derived from CD14+CD34+ precursors are also capable of reverse transendothelial migration and extracellular matrix (ECM) invasion using the urokinase plasminogen activator receptor (uPAR). We found that these cells respond to macrophage-inflammatory protein (MIP)-1alpha, enhancing their ability to invade ECM and supporting the idea that immature DC are selectively recruited at the site of inflammation to expand the pool of APCs. Interestingly, MIP-1alpha was also capable of preventing the decreased matrix invasion observed by blocking uPAR, suggesting that the uPA/uPAR system and MIP-1alpha cooperate in driving immature DC migration through the subendothelial matrix. Upon exposure to maturating stimuli, such as TNF-alpha, CD14+CD34+-derived DC enhance their APC function and decrease the capacity of invading ECM; these changes are accompanied by altered expression and function of uPAR. Moreover, mature DC shift their sensitivity from MIP-1alpha to MIP-3beta, enhancing their transendothelial migration capability in response to the latter chemokine. Our data support the hypothesis that bloodborne DC can move through ECM toward the site of pathogen entry where they differentiate into fully mature APCs with their motility and function regulated by microenvironmental stimuli, including MIP-1alpha, MIP-3beta, and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623814     DOI: 10.4049/jimmunol.164.2.712

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

Authors:  Y Wei; J A Eble; Z Wang; J A Kreidberg; H A Chapman
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

2.  Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

3.  Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication.

Authors:  Massimo Alfano; Nicolai Sidenius; Barbara Panzeri; Francesco Blasi; Guido Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

Review 4.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

5.  Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.

Authors:  Dan Ilkovitch; Diana M Lopez
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

6.  Mining microarray expression data by literature profiling.

Authors:  Damien Chaussabel; Alan Sher
Journal:  Genome Biol       Date:  2002-09-13       Impact factor: 13.583

7.  The serine protease plasmin triggers expression of the CC-chemokine ligand 20 in dendritic cells via Akt/NF-κB-dependent pathways.

Authors:  Xuehua Li; Tatiana Syrovets; Thomas Simmet
Journal:  J Biomed Biotechnol       Date:  2012-10-14

8.  Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.

Authors:  N Ahmed; K Oliva; Y Wang; M Quinn; G Rice
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.